Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.36 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CHUK | O15111 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3232497 | 0.98 | GAA (0.45) | GAABCL2A1NFATC1GSK3BDYRK1A | |
| Water SCHEMBL29955700 | 0.98 | GAA (0.45) | GAABCL2A1NFATC1GSK3BDYRK1A | |
| Water SCHEMBL452432 | 0.98 | GAA (0.45) | GAABCL2A1NFATC1GSK3BDYRK1A | |
| SCHEMBL2175515 | 0.82 | GAA (0.41) | GAAROCK2ROCK1PREPFAP | |
| SCHEMBL29952734 | 0.74 | KDM4E (0.38) | KDM4ESIRT3TDP1 | |
| SCHEMBL22489854 | 0.74 | KDM4E (0.38) | KDM4ESIRT3TDP1 | |
| SCHEMBL708913 | 0.74 | SIRT3 (0.41) | GAACYP3A4MAPTCCNCCDK8 | |
| SCHEMBL17112797 | 0.74 | GAA (0.33) | GAA | |
| SCHEMBL112132 | 0.73 | — | — | |
| SCHEMBL30338917 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569640-A | Preparation method of parol racemate | 安徽英特美科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4737448-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF | Artivila (ShenZhen) Innovation Center, Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12492194-B2 | HPK1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-09 | — | — | US | disclosed |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-3947366-B1 | HPK1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-20250134890-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2025-05-01 | — | — | US | disclosed |
| US-7094790-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1620434-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004101559-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | GAA 4133/4885BCL2A1 797/4885NFATC1 3900/4885 |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | GAA 2044/4885BCL2A1 3228/4885NFATC1 547/4885 |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | GAA 1962/4885BCL2A1 2272/4885NFATC1 1280/4885 |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | HRH4, HRH3, HRH2 | GAA 1225/4885BCL2A1 857/4885NFATC1 1727/4885 |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | GAA 1593/4885BCL2A1 3487/4885NFATC1 1106/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | GAA 3930/4885BCL2A1 731/4885NFATC1 1566/4885 |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | GAA 1962/4885BCL2A1 2272/4885NFATC1 1280/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | GAA 1818/4885BCL2A1 2015/4885NFATC1 1913/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | GAA 3721/4885BCL2A1 1749/4885NFATC1 2548/4885 |
| US-20250134890-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | G6PD, DPYD, DHFR | GAA 2170/4885BCL2A1 1176/4885NFATC1 708/4885 |
| US-12492194-B2 | HPK1 inhibitors | PGK1, PCK1, PDXK | GAA 927/4885BCL2A1 3054/4885NFATC1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.